Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per share in an all-cash transaction, ...

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers new clues for future therapies.

Eilean Therapeutics LLC has announced it is advancing ZE74-0282 into first-in-human development, with the submission of an IND application and enrollment planned to begin in the first quarter of next ...

Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to ...

Med-tech M&A value in 2025 totaled about $38.99 billion through November, reflecting a clear slowdown from 2024’s $57.92 billion and well below the peak years of 2021 and 2022, when 11-month totals ...

Biopharma happenings, including deals and partnerships, and other news in brief: Alnylam, Astrazeneca, Caris, Compugen, Eli Lilly, Medi&Gene, Norgine, Protalix, Roche, Secarna, Vir, Vyne, Yarrow.

The BioWorld Biopharmaceutical Index extended its autumn rally after a more modest September, finishing November up 23.41% for the year. The gain lagged the Nasdaq Biotechnology Index, which surged 34 ...

The FDA’s final guidance for the use of real-world evidence (RWE) was touted by FDA commissioner Marty Makary as opening the door to the use of existing de-identified data in premarket device ...

Eli Lilly and Co. disclosed positive top-line data from the phase III Attain-Maintain trial with orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist. The compound was tested for ...

Co. Ltd. has synthesized cyclosporin derivatives acting as peptidyl-prolyl cis-trans isomerase F, mitochondrial (PPIF; cyclophilin D) and/or peptidyl-prolyl cis-trans isomerase A (PPIA; cyclophilin A; ...

Acute lung injury (ALI) is a severe condition marked by uncontrolled lung inflammation and tissue damage, often leading to respiratory failure. Excessive immune activation recruits neutrophils that ...

Zelluna ASA has submitted a clinical trial application (CTA) to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for ZI-MA4-1 (ZIMA-101), the company’s lead candidate. ZI-MA4-1 is a ...